Background: Goals of management in patients with heart failure and reduced ejection
fraction include reducing death and hospitalizations, and improving health status …

BACKGROUND: Patients with heart failure (HF) have a high burden of symptoms and
physical limitations, regardless of ejection fraction (EF). Whether the benefits of SGLT2 …

Aims We examined the efficacy and safety of dapagliflozin, compared with placebo,
according to aetiology in patients with heart failure (HF) with reduced ejection fraction …

Background: Outcome trials in patients with type 2 diabetes mellitus have demonstrated
reduced hospitalizations for heart failure (HF) with sodium-glucose co-transporter-2 …

Background: In the DAPA-HF trial (Dapagliflozin and Prevention of Adverse Outcomes in
Heart Failure), dapagliflozin, added to guideline-recommended therapies, reduced the risk …

Importance Women may respond differently to certain treatments for heart failure (HF) with
reduced ejection fraction (HFrEF) than men. Objective To investigate the efficacy and safety …

Background: The DAPA-HF trial (Dapagliflozin and Prevention of Adverse-Outcomes in
Heart Failure) showed that dapagliflozin added to other guideline-recommended therapies …

Background Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of
hospitalization for heart failure and cardiovascular death among patients with chronic heart …

Patients with heart failure and preserved ejection fraction (HFpEF) have a high burden of
symptoms and functional limitations, and have a poor quality of life. By targeting …

Whether the sodium–glucose cotransporter 2 inhibitor dapagliflozin reduces the risk of a
range of morbidity and mortality outcomes in patients with heart failure regardless of ejection …